已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Comparative Efficacy of IL-12/23 and IL-23 Inhibitors for Induction and Maintenance Therapy in Moderate to Severe Crohn’s Disease: A Systematic Review and Network Meta-Analysis

克罗恩病 医学 疾病 荟萃分析 维持疗法 重症监护医学 内科学 化疗
作者
Mohammad Al Hayek,Bisher Sawaf,Mohammed S. Beshr,Ahmad Kassem,Dahham Alsoud,Mulham Alom,Rana H. Shembesh,Abdelaziz H. Salama,Yusuf O. Hallak,Shahem Abbarh,Elias Batikh,Mosa Shibani,Muhammed Elhadi,Anita Afzali,Miguel Regueiro
出处
期刊:Inflammatory intestinal diseases [Karger Publishers]
卷期号:10 (1): 1-26
标识
DOI:10.1159/000547707
摘要

Background: Interleukin (IL)-12/23 and IL-23 inhibitors have emerged as promising therapeutic options for moderate-to-severe Crohn’s disease (CD), but comparative data between agents remain limited. This study aimed to assess and rank the efficacy of IL-12/23 and IL-23 inhibitors across key clinical and endoscopic outcomes using network meta-analysis. Methods: We included randomized controlled trials (RCTs) evaluating IL-12/23 (ustekinumab) and IL-23 inhibitors (risankizumab, mirikizumab, guselkumab, briakinumab, and MEDI2070) versus placebo or each other in adult patients with moderate-to-severe CD. Primary outcomes included clinical and endoscopic remission (assessed at the end of the induction and maintenance phases) and corticosteroid-free clinical remission (assessed at the end of the maintenance phase). Risk ratios (RRs) were estimated using a random-effects model. All analyses were conducted in R using the netmeta package. Surface Under the Cumulative Ranking Curve (SUCRA) analysis was used to rank treatments across these endpoints. Results: Fourteen RCTs involving 4,464 patients during the induction phase and 2,601 patients during the maintenance phase were included. Guselkumab achieved the highest clinical remission rate compared to placebo at the end of both the induction phase (RR = 2.62; 95% CI, 2.03–3.39; SUCRA: 91%) and the maintenance phase (RR = 2.37; 95% CI, 1.64–3.42; SUCRA: 85%). In addition, guselkumab was superior to mirikizumab in terms of clinical remission at the end of the induction phase (RR = 1.66; 95% CI, 1.16–2.37). Guselkumab was also the most effective agent for achieving corticosteroid-free clinical remission compared to placebo (RR = 3.06; 95% CI, 1.52–6.16; SUCRA: 78%) at the end of the maintenance phase. Mirikizumab achieved the highest endoscopic remission rate compared to placebo at the end of both the induction phase (RR = 3.52; 95% CI, 1.50–8.27; SUCRA: 78%) and the maintenance phase (RR = 5.84; 95% CI, 2.76–12.37; SUCRA: 88%). Furthermore, mirikizumab, guselkumab, and risankizumab were superior to ustekinumab in terms of endoscopic remission at the end of the maintenance phase. Conclusions: These findings suggest guselkumab as a potential first-line therapy for patients presenting with predominant clinical symptoms, offering the additional benefit of reducing corticosteroid use and its associated long-term risks. Conversely, mirikizumab may be the preferred option for patients with persistent mucosal inflammation, owing to its superior efficacy in achieving endoscopic remission.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
cheqi完成签到 ,获得积分10
1秒前
1秒前
荔枝完成签到 ,获得积分10
1秒前
jinjinjin完成签到 ,获得积分10
1秒前
查不到我就吃饭完成签到 ,获得积分10
1秒前
故然完成签到 ,获得积分10
2秒前
hanhan完成签到 ,获得积分10
2秒前
lzl007完成签到 ,获得积分0
2秒前
谎1028完成签到 ,获得积分10
4秒前
爆米花糖完成签到 ,获得积分10
5秒前
5秒前
所所的应助被bibai28采纳,获得20
5秒前
WUXICG完成签到 ,获得积分10
6秒前
Lan完成签到 ,获得积分10
8秒前
淡定又夏完成签到 ,获得积分10
8秒前
泡泡糖完成签到,获得积分10
8秒前
8秒前
马达发布了新的文献求助10
9秒前
safeandsound完成签到 ,获得积分10
9秒前
清浔完成签到 ,获得积分10
9秒前
wa完成签到 ,获得积分10
10秒前
多出成果卖煎饼果子完成签到 ,获得积分10
10秒前
daddadadada完成签到 ,获得积分10
11秒前
auRoRa完成签到,获得积分10
11秒前
淡然雁易完成签到 ,获得积分10
11秒前
张辰熙完成签到 ,获得积分10
11秒前
12秒前
许易安完成签到 ,获得积分10
12秒前
缪慧敏完成签到,获得积分20
13秒前
落雁归南山完成签到 ,获得积分10
14秒前
笔至梦花完成签到 ,获得积分10
14秒前
要减肥的冥完成签到,获得积分20
14秒前
落寞代桃完成签到 ,获得积分10
14秒前
等待黎明完成签到,获得积分10
14秒前
多巴胺完成签到 ,获得积分10
15秒前
长情的觅荷完成签到,获得积分10
15秒前
秋风完成签到,获得积分0
17秒前
亚蛋求学完成签到 ,获得积分10
17秒前
17秒前
马可菠萝包完成签到 ,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189866
求助须知:如何正确求助?哪些是违规求助? 9577019
关于积分的说明 21851254
捐赠科研通 7787798
什么是DOI,文献DOI怎么找? 3435795
关于科研通互助平台的介绍 2559856
邀请新用户注册赠送积分活动 2482699